CN110869012B - 用于减少肝脏脂肪的3-羟基丁酸化合物 - Google Patents

用于减少肝脏脂肪的3-羟基丁酸化合物 Download PDF

Info

Publication number
CN110869012B
CN110869012B CN201880042880.5A CN201880042880A CN110869012B CN 110869012 B CN110869012 B CN 110869012B CN 201880042880 A CN201880042880 A CN 201880042880A CN 110869012 B CN110869012 B CN 110869012B
Authority
CN
China
Prior art keywords
liver
subject
fat
compound
fatty liver
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880042880.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN110869012A (zh
Inventor
K·克拉克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tederta Co ltd
Original Assignee
Tederta Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tederta Co ltd filed Critical Tederta Co ltd
Publication of CN110869012A publication Critical patent/CN110869012A/zh
Application granted granted Critical
Publication of CN110869012B publication Critical patent/CN110869012B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Meat, Egg Or Seafood Products (AREA)
CN201880042880.5A 2017-06-27 2018-06-22 用于减少肝脏脂肪的3-羟基丁酸化合物 Active CN110869012B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1710229.4 2017-06-27
GBGB1710229.4A GB201710229D0 (en) 2017-06-27 2017-06-27 Compounds for new use
PCT/GB2018/051752 WO2019002828A1 (en) 2017-06-27 2018-06-22 3-HYDROXYBUTYRATE COMPOUNDS FOR USE IN THE REDUCTION OF HEPATIC FAT

Publications (2)

Publication Number Publication Date
CN110869012A CN110869012A (zh) 2020-03-06
CN110869012B true CN110869012B (zh) 2024-06-11

Family

ID=59523693

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880042880.5A Active CN110869012B (zh) 2017-06-27 2018-06-22 用于减少肝脏脂肪的3-羟基丁酸化合物

Country Status (13)

Country Link
US (2) US12439944B2 (https=)
EP (2) EP4215189A1 (https=)
JP (2) JP7374000B2 (https=)
KR (1) KR102680437B1 (https=)
CN (1) CN110869012B (https=)
AU (1) AU2018293398B2 (https=)
CA (1) CA3066948A1 (https=)
DK (1) DK3644982T3 (https=)
ES (1) ES2945964T3 (https=)
GB (2) GB201710229D0 (https=)
PL (1) PL3644982T3 (https=)
TW (1) TWI811222B (https=)
WO (1) WO2019002828A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201710229D0 (en) * 2017-06-27 2017-08-09 Tdeltas Ltd Compounds for new use
GB201715654D0 (en) 2017-09-27 2017-11-08 Tdeltas Ltd Method of treatment
GB2577723A (en) 2018-10-04 2020-04-08 Tdeltas Ltd Compounds for new use
ES2941943T3 (es) 2019-01-17 2023-05-26 Ketolipix Therapeutics Gmbh Método para la producción de glicéridos de ácidos hidroxicarboxílicos
CN109700021A (zh) * 2019-03-04 2019-05-03 清华大学 3-羟基丁酸及其衍生物在制备预防和治疗肥胖及肥胖相关疾病的产品中的应用
CN110776425B (zh) * 2019-10-23 2021-02-26 清华大学 一种(r)-3-羟基丁酸及其低聚物的制备方法
JP7638693B2 (ja) * 2020-12-15 2025-03-04 大阪瓦斯株式会社 ヒドロキシアルカン酸結晶の製造方法及びヒドロキシアルカン酸の結晶多形体
US20240196917A1 (en) * 2021-06-01 2024-06-20 Osaka Gas Co., Ltd. Oil and fat composition containing 3-hydroxybutyric acid
WO2023283654A1 (en) * 2021-07-09 2023-01-12 Georgia State University Research Foundation, Inc. The use of beta-hydroxybutyrates for the treatment or prevention of aneurysms and dissections
IT202100020441A1 (it) * 2021-07-30 2023-01-30 Unichem Estense S R L Miscela di un mono-estere e un di-estere, in cui detti mono-estere e di-estere sono esteri dell’acido (R)-3-idrossibutanoico con un polialcol, processo per la preparazione della miscela e relativi usi medici
CN113712140A (zh) * 2021-09-13 2021-11-30 珠海麦得发生物科技股份有限公司 一种含(r)-3羟基丁酸的固体饮料及其制备方法
AU2022381752B2 (en) * 2021-11-04 2026-01-08 Vdf Futureceuticals, Inc Ketone precursors and methods therefor
CN118591523A (zh) * 2021-11-12 2024-09-03 阿萨达股份公司 多元醇衍生的化合物
AU2022411334A1 (en) * 2021-12-14 2024-06-13 Suntory Holdings Limited Carbonated beverage, and method for enhancing sense of carbonation of beverage
CN118382365A (zh) * 2021-12-14 2024-07-23 三得利控股株式会社 含有3羟基丁酸及低级脂肪族醇的饮料及呈味改善方法
JP7223193B1 (ja) 2022-05-26 2023-02-15 大阪瓦斯株式会社 内臓脂肪低減剤およびその用途
CN116966173A (zh) * 2023-06-15 2023-10-31 浙江大学 3-羟基苯乙酸在制备改善非酒精性脂肪肝药物中的应用
CN118903420A (zh) * 2024-07-02 2024-11-08 南方医科大学 Irf4抑制剂在治疗非酒精性脂肪性肝炎的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004108740A2 (en) * 2003-06-03 2004-12-16 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nutritional supplements and therapeutic compositions comprising (r)-3-hydroxybutyrate derivatives
WO2010021766A1 (en) * 2008-08-21 2010-02-25 Isis Innovation Limited Hydroxybutyrate ester and medical use thereof
CN105377246A (zh) * 2013-04-22 2016-03-02 卡迪拉保健有限公司 针对非酒精性脂肪性肝病(nafld)的新组合物

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1248321B (it) * 1991-05-15 1995-01-05 Sigma Tau Ind Farmaceuti Uso di esteri di acil l-carnitine con l'acido gamma-idrossibutirrico per produrre composizioni farmaceutiche per il trattamento di epatopatie
US6323237B1 (en) 1997-03-17 2001-11-27 Btg International Limited Therapeutic compositions
US20090253781A1 (en) 2002-05-24 2009-10-08 Btg International Limited Therapeutic compositions
CN1315473C (zh) 1997-03-17 2007-05-16 英国技术集团国际有限公司 治疗组合物
EP2258742A1 (en) * 1997-12-22 2010-12-08 Metabolix, Inc. Polyhydroxyalkanoate compositons having controlled degradation rates
EP2275468A1 (en) * 2000-07-14 2011-01-19 Metabolix, Inc. Polyurethanes obtained from hydroxyalkanoates and isocyanates
SE0400355D0 (sv) * 2004-02-17 2004-02-17 Synbiotics Ab New synbiotec use
WO2006020137A2 (en) * 2004-07-16 2006-02-23 Ketocytonyx Inc. Oligomeric compounds
EP1778615A4 (en) 2004-07-20 2010-01-06 Btg Int Ltd OLIGOMERE KETONE COMPOUNDS
WO2008110034A1 (en) 2007-03-14 2008-09-18 Shantou University 3-hydroxy fatty acid and its derivatives for improving of learning and/or memory of subjects
EP2240017B1 (en) 2008-01-04 2019-03-13 Oxford University Innovation Limited Ketone bodies and ketone body esters as blood lipid lowering agents
US8642654B2 (en) 2009-04-16 2014-02-04 Isis Innovation Limited Hydroxybutyrate ester and medical use thereof
WO2011078204A1 (ja) 2009-12-24 2011-06-30 浜理薬品工業株式会社 高脂血症の予防または治療剤、および抗疲労剤
US8865641B2 (en) * 2011-06-16 2014-10-21 The Feinstein Institute For Medical Research Methods of treatment of fatty liver disease by pharmacological activation of cholinergic pathways
GB201206192D0 (en) 2012-04-05 2012-05-23 Tdeltas Ltd Ketone bodies and ketone body esters and for maintaining or improving muscle power output
GB2515603B (en) 2013-03-14 2015-10-14 Isis Innovation Process for producing (R)-3-Hydroxybutyl (R)-3-Hydroxybutyrate
CA2902603C (en) 2013-03-19 2021-03-02 University Of South Florida Compositions and methods for producing elevated and sustained ketosis
US11814664B2 (en) * 2013-05-24 2023-11-14 Genomatica, Inc. Microorganisms and methods for producing (3R)-hydroxybutyl (3R)-hydroxybutyrate
GB201314127D0 (en) 2013-08-07 2013-09-18 Tdeltas Ltd Ketone body and ketone body ester for reducing muscle breakdown
US20150283163A1 (en) 2014-04-04 2015-10-08 Organic Medical Ventures, L.L.C. Muscle treatment composition and method making same
US20180008629A1 (en) 2015-01-29 2018-01-11 Yale University Compositions and Methods for Treating NLRP3 Inflammasome-Related Diseases and Disorders
EA201791982A1 (ru) * 2015-03-09 2020-02-17 Интекрин Терапьютикс, Инк. Способы лечения неалкогольной жировой болезни печени и/или липодистрофии
CA3021784A1 (en) 2016-04-19 2017-10-26 Keto Patent Group, Inc. Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans
US10336812B2 (en) * 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
GB201710229D0 (en) 2017-06-27 2017-08-09 Tdeltas Ltd Compounds for new use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004108740A2 (en) * 2003-06-03 2004-12-16 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nutritional supplements and therapeutic compositions comprising (r)-3-hydroxybutyrate derivatives
WO2010021766A1 (en) * 2008-08-21 2010-02-25 Isis Innovation Limited Hydroxybutyrate ester and medical use thereof
CN105377246A (zh) * 2013-04-22 2016-03-02 卡迪拉保健有限公司 针对非酒精性脂肪性肝病(nafld)的新组合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Creatine Supplementation may prevent NAFLD by stimulating fatty acid oxidation;Rene L Jacobs等;《The FASEB Journal》;20130401;第27卷(第S1期);第222.2页 *

Also Published As

Publication number Publication date
US12439944B2 (en) 2025-10-14
AU2018293398A1 (en) 2020-01-16
TW201904568A (zh) 2019-02-01
JP2023120442A (ja) 2023-08-29
KR102680437B1 (ko) 2024-07-01
EP4215189A1 (en) 2023-07-26
AU2018293398B2 (en) 2023-11-23
JP7632979B2 (ja) 2025-02-19
ES2945964T3 (es) 2023-07-11
GB201810300D0 (en) 2018-08-08
JP7374000B2 (ja) 2023-11-06
EP3644982A1 (en) 2020-05-06
CA3066948A1 (en) 2019-01-03
KR20200019745A (ko) 2020-02-24
GB2567273A (en) 2019-04-10
TWI811222B (zh) 2023-08-11
CN110869012A (zh) 2020-03-06
DK3644982T3 (da) 2023-07-17
JP2020527547A (ja) 2020-09-10
US20200113220A1 (en) 2020-04-16
PL3644982T3 (pl) 2023-08-14
GB2567273B (en) 2020-10-07
WO2019002828A1 (en) 2019-01-03
US20260007157A1 (en) 2026-01-08
GB201710229D0 (en) 2017-08-09
EP3644982B1 (en) 2023-04-12

Similar Documents

Publication Publication Date Title
CN110869012B (zh) 用于减少肝脏脂肪的3-羟基丁酸化合物
US20230355563A1 (en) Hunger suppression
US20120010285A1 (en) Agent for promoting energy consumption
US12226387B2 (en) Compounds for use in cancer cachexia
CN112996498A (zh) 在预防或治疗运动员过度训练中使用的化合物
KR100886466B1 (ko) 신규한 스티그마스테롤 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법, 및 이를 포함하는 비만억제 또는 고지혈증 예방 및 치료용 조성물
KR20130075442A (ko) 4-하이드록시 타목시펜 유사체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는, 대사증후군 관련 질환의 예방 또는 치료용 조성물
WO2021132697A1 (ja) ステビオールの新規用途
US20180369162A1 (en) Novel use of pinocarveol

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant